/PRNewswire/ CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel treatments for neurological diseases, announced today.
Auburn University research providing hope for children with deadly disease GM1 alabamanewscenter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from alabamanewscenter.com Daily Mail and Mail on Sunday newspapers.
Jojo is experiencing life like most 13-year-old girls: staying up later, watching movies, shopping and baking cookies. And now she has more liberty, but it s a different kind of freedom.
The Translational Institute for Molecular Therapeutics leverages UMass Chan Medical School’s extensive experience in researching and developing gene therapies for early-stage clinical trials. Miguel Sena-Esteves, PhD, is director of the new institute.
Sio Gene Therapies, a clinical-stage company focused on developing gene therapies for neurodegenerative diseases, presented positive interim data from its Phase I/II study of AXO-AAV-GM1, an adeno-associated viral vector-based gene therapy candidate for GM1 gangliosidosis that was licensed from UMass Chan.